BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...II for ADC in EGFR-mutated NSCLCDaiichi Sankyo Co. Ltd. (Tokyo:4568) presented Phase I data for patritumab...
BioCentury | May 24, 2018
Product R&D

Bias-less bispecifics

...of Roche. Several companies have tested HER3 inhibitors in combination with Herceptin or Perjeta, including patritumab...
...levels were defined as greater than 100-fold above the EC 90 . Comparators included Daiichi’s patritumab...
...potently inhibits HER3 signaling via HER2-guided ligand blockade.” Cancer Cell (2018) Michael Leviten, Senior Writer patritumab (AMG 888, U3-1287) Seribantumab...
BioCentury | Nov 4, 2016
Clinical News

Patritumab: Ph II ongoing

...Daiichi said patritumab will be evaluated in the ongoing Phase II I-SPY 2 trial, which is...
...in which a compound has an 85% chance of success in a Phase III trial. Patritumab...
...Thousand Oaks, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Patritumab ( AMG 888 , U3-1287...
BioCentury | Jun 6, 2016
Clinical News

Patritumab: Phase III discontinued

...Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC...
...IDMC did not identify any safety issues. The company said a Phase II trial of patritumab...
...Thousand Oaks, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Patritumab ( U3-1287 , AMG 888...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

...two other anti-ERBB3 mAbs: seribantumab ( MM-121 ) from Merrimack Pharmaceuticals Inc. and patritumab ( AMG 888...
...in Phase II testing for breast cancer, non-small cell lung cancer and ovarian cancer, while patritumab...
BioCentury | Sep 9, 2013
Strategy

Setting Amgen's targets

...final data collection for primary endpoints over 2013-14] From 2012 acquisition of Micromet Inc AMG 888 (U3-1287...
BioCentury | Jun 6, 2013
Cover Story

Driving cancer through ErbB3

...and ErbB3 Phase II Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) / Amgen Inc. (NASDAQ:AMGN) U3-1287, AMG 888...
BioCentury | Mar 24, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer HER2 (EGFR2; ERBB2; neu); epidermal growth factor receptor 3 (EGFR3; HER3; ERBB3) Mouse and patient tissue studies suggest that...
BioCentury | Mar 7, 2011
Strategy

Daiichi's U.S. comPlexx

...German biotech with a pipeline of antibodies for cancer. The lead candidate is U3-1287 ( AMG 888...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Cancer

...bispecific antibody targeting ERBB3 and ERBB2 (HER2; neu), is in Phase I/II testing for cancer. AMG 888...
Items per page:
1 - 10 of 19